In the red since 2020, Euroapi, a former subsidiary of Sanofi, will receive up to 140 million euros in public aid.

Active pharmaceutical ingredient specialist Euroapi, a former Sanofi subsidiary that is continuing its recovery plan, announced on Tuesday, July 29, an agreement with the government for public aid of up to €140 million. The French manufacturer also announced that it had reduced its losses in the first half of the year.

"The French government and Euroapi signed, on July 28, 2025, a contractual agreement for public aid of up to €140 million to support investments" linked to the important project of common European interest (IPCEI) dedicated to the pharmaceutical sector, the company reported in a press release.

In the red since 2020, Euroapi saw its results deteriorate in 2023 and launched a four-year strategic plan in 2024 aimed at streamlining its activities and selling some of its six industrial sites.

The company was hit hard in 2024 by the shutdown of its Brindisi, Italy, site. At the end of June, it sold its Haverhill, UK, factory and its 160 jobs to the British company Particle Dynamics. The capital gain from this sale affected gross operating surplus "by €4.7 million" in the first half of the year, according to Euroapi, which now employs 3,270 people.

The group reduced its net loss to €28.5 million in the first half of the year, compared to a loss of €34.8 million in the same period a year earlier. Its half-year revenue fell by 8.2% to €412.1 million, due in particular to a decrease in sales to its former parent company Sanofi.

Euroapi now expects annual revenue to be "moderately down" rather than the "slight to stable" decline initially forecast. It confirmed its target for a rebound in gross operating profit margin this year, which should be between 7% and 9% of revenue, this time aiming for "the upper end of the range" .